Abstract:Background Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performance of plasma biomarkers across the entire Alzheimer’s continuum in the Chinese population. Methods Plasma amyloid-β (Αβ)42, Aβ40, Aβ42/Aβ40, phosphorylated tau (p-tau)181, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were measured utilizing the ultrasensitive single-molecule array technology across the AD continuum ( n =206), wherein Aβ status was defined by the values of cerebrospinal fluid (CSF) Aβ42 or Aβ positron emission tomography (PET). Their trajectories were compared with those of putative CSF biomarkers. Results Plasma GFAP and p-tau181 increased only in Aβ-positive individuals throughout aging, whereas NfL increased with aging regardless of Aβ status. Among the plasma biomarkers studied, GFAP was the one that changed first. It had a prominent elevation early in the cognitively unimpaired (CU) A+T− phase (CU A+T− phase: 97.10±41.29 pg/ml; CU A−T− phase: 49.18±14.39 pg/ml; p <0.001). From preclinical to symptomatic stages of AD, plasma GFAP started to rise sharply as soon as CSF Aβ became abnormal and continued to increase until reaching its highest level during the AD dementia phase. The greatest slope of change was seen in plasma GFAP. This is followed by CSF p-tau181 and total-tau, and, to a lesser extent, then plasma p-tau181. In contrast, the changes in plasma NfL, Aβ42/Aβ40, Aβ42, and Aβ40 were less pronounced. Of note, these plasma biomarkers exhibited smaller dynamic ranges than their CSF counterparts, except for GFAP which was the opposite. Plasma GFAP and p-tau181 were tightly associated with AD pathologies and amyloid tracer uptake in widespread brain areas. Plasma GFAP could accurately identify CSF Aβ42 (area under the curve (AUC)=0.911) and Aβ PET (AUC=0.971) positivity. Plasma p-tau181 also performed well in discriminating Aβ PET status (AUC=0.916), whereas the discriminative accuracy was relatively low for other plasma biomarkers. Conclusions This study is the first to delineate the trajectories of plasma biomarkers throughout the Alzheimer’s continuum in the Chinese population, providing important implications for future trials targeting plasma GFAP to facilitate AD prevention and treatment.

[Chinese guideline for clinical application of fluid biomarkers for Alzheimer's disease(2024 edition)]

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

The Fluid Biomarkers of Alzheimer’s Disease

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Current state of Alzheimer’s fluid biomarkers

Body fluid biomarkers in Alzheimer's disease.

Clinical and Research Value of the New Diagnostic Criteria for Alzheimer's Disease.

The clinical applications and prospects of Cerebrospinal fluid biomarkers in the diagnosis of Alzheimer’s disease

Biomarkers for Early Diagnosis of Alzheimer's Disease in Body Fluids

Cerebrospinal Fluid and Blood Biomarkers in the Diagnostic Assays of Alzheimer’s Disease

Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics

Biomarkers of Alzheimer'S Disease in Body Fluids

Blood‐based Biomarkers of Alzheimer's Disease: Standardization and Comprehensiveness

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer's Disease

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

Early diagnosis of Alzheimer's disease in plasma and cerebrospinal fluid levels of Aβ42 and tau

Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments

Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease

The Dynamics of Plasma Biomarkers Across the Alzheimer’s Continuum

Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China